Roles and practices of specialist lung cancer nurses: a scoping review protocol

Brunelli, Vanessa; Ramis, Mary-Anne; Kynoch, Kathryn

doi:10.11124/jbies-22-00047

Cited by 1 publication

(27 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…TO 044 | Epithelial-mesenchymal transition changes in smokers with non-small cell lung cancer Lu W 1,3 , Chia C 3,2,1 , Larby J 2,1 , Haug G 2,1 , Hardikar A 4,1 , Singhera G 5 , Hackett T 5 , Robertson I 1 , Eapen M 1 , Sohal S Introduction/Aim: Epithelial-mesenchymal transition (EMT) might be central to lung cancer development in smokers and COPD. We now illustrate EMT changes in a broader demographic of patient groups diagnosed with nonsmall cell lung cancer (NSCLC) (adenocarcinoma and squamous cell carcinoma).…”

Section: Discussionmentioning

confidence: 99%

“…TO 050 | Investigating the effects of occupational dust exposures on respiratory health Horvat J 1 , Vanka K 1 , Kim R 1,2 , Brown A 1 , Donovan C 1,2 , Ali M 1,3 , Gomez H 1 , Palanisami T 4 , James C 5 , Williams K 6 , Ilic D 6 , Hansbro P…”

Section: Discussionmentioning

confidence: 99%

“…TO 092 | Adverse neonatal outcomes in pregnant women with asthma; updated meta-analysis Robijn A 1 , Harvey S 1 , Jensen M 1 , Quek D 2 , Smith H 2 , Atkins S 2 , Chua R 2 , Wang G 3 , Chambers C 4 , Namazy J 8 , Schatz M 5 , Gibson P 1,6,7 , Murphy V Introduction/Aim: A systematic review and meta-analysis from 2013 reported increased risks of congenital malformations, neonatal death and neonatal hospitalisation among infants born to women with asthma compared to infants born to mothers without asthma. This systematic review and meta-analysis aimed to provide updated associations between maternal asthma and adverse neonatal outcomes.…”

Section: Discussionmentioning

confidence: 99%

“…TO 120 | COVID pneumonitis, a risk factor for persistent lung allograft dysfunction TO 123 | SARS-CoV-2 spike fails to induce inflammation in paediatric airway cells Ho R 1,2,3 , Laing I 1,2 , Ling K 2,6 , Laucirica D 1,2 , Stick S 2,4,5 , Kicic A 2,4,5,6 , WAERP…”

Section: Discussionmentioning

confidence: 99%

“…Seven studies were based on the perspective of people with ILD, 2 on caregivers only, 2 included people with ILD and caregivers and 1 on physicians' experiences. The three most commonly represented TDF domains and associated barriers were: (1) Beliefs about consequences (e.g., stigma, loss of spontaneity, inevitability of oxygen use, irreversible changes to lifestyle); (2) Environmental context and resources (e.g., burdensome equipment, restriction to valued activities, costs, funding); and (3) Emotion (fear, anxiety, depression, anger, regret). Facilitators of oxygen use included experiencing symptom relief, equipment that was lighter and more portable, having adequate information on 'how to use' and knowledge about 'why' oxygen was prescribed and the possible benefits and associated challenges, access to an "oxygen buddy", and reduced worry for careers.…”

Section: Discussionmentioning

confidence: 99%

See 4 more Smart Citations

TSANZ Abstracts

2023

Respirology

View full text Add to dashboard Cite

Introduction/Aim: Patients with respiratory diseases are more susceptible to viral infection and develop more severe symptoms, associated with immunosuppression by elevated transforming growth factor-beta (TGFβ). Glucocorticosteroids (GCS) effectively reduce inflammation when inhaled prophylactically, or taken orally for exacerbations, but can also cause further immunosuppression. Oral pirfenidone (PFD), an anti-fibrotic used to treat patients with pulmonary fibrosis, has been shown to reduce TGFβ-enhanced influenza A virus (IAV) infection in mice (Thomas et al., Respirology, 2021). The current aim was to determine if administration of inhaled PFD prior to infection, or with the addition of oral PFD post-infection, is as effective at reducing IAV-induced inflammation as GCS, without causing immunosuppression. Methods: Mice were treated with i.n. vehicle (control), PFD (13.3 mg/kg) or GCS (1 mg/kg) daily, starting 2 days prior to infection with IAV (10 2 PFU, HKx31, n = 6-10). Separate mice were treated daily pre-and post-infection (i.n. then oral) with vehicle (i/o control), PFD (i/o PFD) or GCS (i/o GCS). Mice were culled 3 days post-infection to measure viral load, inflammation and immune responses in BALF and lung tissue. Results: Inhaled PFD, but not GCS, reduced viral load (p < 0.05). Both PFD and GCS reduced RANTES, while PFD, but not GCS, reduced IL-6, TNFα and KC. IAVinduced Inflammatory cells, notably macrophages and neutrophils, were further increased by GCS (p < 0.001) but not by PFD. Preliminary results suggest that i/o PFD reduced the severity of IAV infection, while i/o GCS increased severity. Conclusion: Treatment with either inhaled or i/o PFD afforded greater protection against TGFβ-enhanced viral infection and inflammation than GCS. These positive findings support the repurposing of PFD beyond its current use in IPF to include other respiratory diseases, offering superior protection from worse disease outcomes associated with viral exacerbations.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%